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Abstract
Background Renal transplantation improves quality of life
(QoL) and survival in children requiring renal replacement
therapy (RRT). Sensitization with development of a broad-
spectrum of anti-HLA antibodies as a result of previous trans-
plantation or after receiving blood products is an increasing
problem. There are no published reports of desensitization
protocols in children allowing renal transplantation from
HLA-antibody-incompatible living donors.
Methods We adopted our well-established adult desensitiza-
tion protocol for this purpose and undertook HLA antibody-
incompatible living donor renal transplants in two children: a
14-year-old girl and a 13-year-old boy.
Results After 2 and 1.5 years of follow-up, respectively, both
patients have stable renal allograft function despite a rise in
donor-specific antibodies in one case.
Conclusions HLA-incompatible transplantation should be
considered in selected cases for sensitized children.
Keywords Pediatric . Transplantation .
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Introduction
Children with end-stage kidney disease (ESKD) on dialysis
have worse outcomes compared with those transplanted [1, 2].
Dialysis has detrimental effects on children’s growth and cog-
nitive development [3, 4]. Many national and international
kidney allocation schemes prioritize children on deceased-
donor waiting lists to ensure short waiting times [5, 6]. The
median waiting time for a pediatric patient in the UK is 339
[95 % confidence interval (CI) 263–415] days [7].
The calculated HLA antibody reaction frequency (cRF)
defines the level of sensitization and is derived from the pro-
portion of the last 10,000 deceased donors exhibiting HLA
antigens that react with a patient’s serum. In the UK, the me-
dian waiting time of a highly sensitized (cRF ≥ 85 %) child is
1241 (95 % CI 836–1646) days, which is no longer advanta-
geous over the adult median waiting time of 1160 (95 % CI
1136–1184) days [7]. Highly sensitized children are also un-
likely to receive kidneys via national living donor kidney
sharing schemes as they are usually sensitized to common
HLA antigens.
HLA-antibody-incompatible renal transplantation means
that the organ expresses HLA antigens to which the recipient
has pre-formed antibodies, resulting in a positive flow cytomet-
ric or cytotoxic crossmatch. Desensitization aims to remove
sufficient antibodies to ensure a lack of reactivity of recipient
serum to donor tissue (negative crossmatch). Living-donor
HLA-antibody-incompatible renal transplantation provides a
significant survival benefit for highly sensitized adult patients
over those remaining on dialysis [8]. The only desensitization
strategies in children reported in the literature have aimed at
reducing their cRF while on the waiting list. A few cases have
been described in which this approach has allowed transplan-
tation of a child with a deceased donor kidney [9, 10].
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There are no published reports of living-donor HLA-
antibody-incompatible kidney transplants in children. It may
be that the perceived risks and lack of experience in antibody
removal in children has made pediatric centers reluctant to
perform such transplants. We introduced our well-
established adult desensitization protocol [11] to the pediatric
transplant unit and undertook HLA-incompatible living-donor
renal transplantation in two children. Our protocol is based on
a test plasma exchange (PEX) to assess feasibility and esti-
mate the number of sessions of antibody removal required to
achieve a negative crossmatch prior to transplant. After the
transplant, antibody removal is not performed for high levels
of donor-specific antibodies (DSA) without accompanying
deterioration in graft function or biopsy-proven rejection.
First case
A 14-year-old white girl with ESKD secondary to congenital
anomalies of the kidney and urinary tract was referred to our
center from another European country. Two years previously,
she had received a pre-emptive renal transplant from a de-
ceased donor, which was complicated by renal vein thrombo-
sis and graft nephrectomy within 24 h of implantation. After
the first transplant, the patient developed anti-HLA antibodies
with multiple specificities and a cRF of 99 %. The only po-
tential living donor was her father, but the crossmatch at the
referring center was positive. The patient was therefore en-
tered into the National Living Donor Kidney Sharing
Scheme (NLDKSS) but was unsuccessful after two runs.
An initial B- and T-cell-flow crossmatch against her father
was positive, with 4.23 and 2.29 relative mean fluorescence
(RMF), respectively. Reactivity was due to an antibody spe-
cific for mismatches HLA-B7 and -DQ8. Neither of these
were repeat mismatches from her first transplant. To assess
the feasibility of antibody removal, the patient underwent a
test PEX. This reduced the level of her DSA, as measuredwith
B7- and DQ-coated beads by Luminex assay, from 6854 to
2181 mean fluorescence intensity (MFI) and from 9346 to
4299 MFI, respectively. Both B- and T-cell-flow crossmatch
were negative after test PEX, with a decrease in RMF to 1.63
and 1.2, respectively. Based on these results, we estimated that
one session of antibody removal would be enough to achieve a
negative crossmatch.
Tacrolimus and mycophenolate mofetil (MMF) were com-
menced 1 week prior to transplantation. Our patient
underwent one session of plasma exchange on the day prior
to her surgery, which reduced DSA from 11602 to 4625 MFI,
following which a dose of immunoglobulin IV (IVIG) 0.5 g/
kg was administrated overnight to prevent antibody rebound.
On the day of surgery, the total DSA MFI was 8333, and B-
and T-cell-flow crossmatches were negative (2 and 1.15 RMF,
respectively). Induction therapy was with anti-thymocyte
globulin (ATG) (1.5 mg/kg for 4 days), and maintenance im-
munosuppression comprised MMF, tacrolimus, and predniso-
lone. Prednisolone was tapered to 10 mg once daily at
6 weeks.
The patient made a good recovery, with plasma creatinine
improving until day 14, at which point it started to rise. This
prompted administration of one dose of methylprednisolone
IV prior to biopsy; biopsy showed no evidence of acute rejec-
tion despite rise in DSA. Plasma creatinine subsequently im-
proved with hydration IVand one dose of methylprednisolone
(Fig. 1). A further biopsy was performed on day 48 because of
persistently raised DSA. There was no evidence of antibody-
mediated rejection according to 2013 Banff criteria in either
biopsy (t0, v0, i0, g0, ti0, ci0, ct0, mm0, cv1, ah1, ptc0) [12].
C4d staining was positive in the peritubular capillaries and
glomeruli on both biopsies.
DSA levels fluctuated during the follow-up period,
reaching values as high as 20,486 MFI for B7 and 19,222
MFI for DQ8 (Fig. 1). As per our protocol, in the absence of
renal allograft dysfunction or histological evidence of rejec-
tion, we avoided antibody removal posttransplant. A protocol
biopsy at 7 months posttransplant showed chronic changes of
tubular atrophy and interstitial fibrosis (∼20 %), along with
chronic vascular changes but no evidence of acute rejection
and negative C4d staining (t0, v0, i0, ti0, g0, ci1, ct1, mm0,
cv2, ah1, ptc0). Two years after transplant, the patient’s renal
function remained stable, with an estimated glomerular filtra-
tion rate (eGFR) of 54 ml/min/1.73 m2 and a reduction in total
donor-specific antibodies to 1499 MFI (B7 629; DQ8 870).
The only infectious complication was a mild upper respiratory
tract infection successfully treated orally with penicillin. The
patient feels well and reports an improved quality of life
(QoL) and has returned to school.
Second case
A 13-year-old boy with ESKD due to solitary dysplastic kid-
ney was referred to our center from the Middle East. He had
been on hemodialysis for 10 months after renal allograft fail-
ure of his first living-donor renal transplant, which was per-
formed 9 years earlier elsewhere and removed 6 months prior
to retransplantation. He also had anti-HLA antibodies with
multiple specificities and a cRF of 99 %. He was not eligible
for deceased donation in the UK, but his mother did wish to
donate to him.
The total MFI of DSA (A23, Cw7, DQB1*06:02, DP1)
was 22,545; B-cell crossmatch was positive, with an RMF
of 3.24. A test PEX showed a reduction in RMF to 2.45 and
a fall in DSA to 15,321. Therefore, two sessions of double-
filtration plasmapheresis (DFPP) were performed prior to his
transplant, resulting in a B-cell-flow crossmatch of 1.68 RMF.
IVIG at 0.5 g/kg was administered after the final session. His
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immunosuppression protocol was the same as described in the
first case above, with the exception of alemtuzumab given at
induction instead of ATG. ATGwas used for the purpose of T-
cell depletion in the first case because at that time we were not
aware of any convincing safety data regarding using
alemtuzumab in children. We had had experience in using
ATG in pediatric recipients for treatment of severe rejection.
Subsequently, data regarding the safety of alemtuzumab in
children became available to us, and decided to use it instead
of ATG for the second case.
This patient made an uneventful recovery from his surgery.
A protocol biopsy at 2 months showed no features of rejection
(t0, v0, i0, g0, ci0, ct0, cg0, mm0, cv1, ah1). C4d staining was
diffusely positive in glomeruli but negative in peritubular cap-
illaries. Plasma creatinine rose soon after biopsy following
hospital admission for viral gastroenteritis. The lowest eGFR
in that period was 24 ml/min/1.73 m2, which returned to base-
line after empirical treatment with three doses of methylpred-
nisolone IV. There was no associated rise in DSA, and two
repeat biopsies showed no rejection with negative C4d stain-
ing. DSA—last measured 7 months posttransplant—was
18,745 MFI (A23 2602 MFI, Cw7 5893 MFI, DQB1*06:02
7112 MFI, DP1 3138 MFI). Latest (fourth) biopsy showed
chronic changes (cv1 and ah1 only) and no features of acute
rejection. Follow-up stood at 1 year at this report, with eGFR
of 55 ml/min/1.73 m2.
Discussion
We undertook successful patient desensitization enabling re-
nal transplantation of two highly sensitized children from their
related HLA-antibody-incompatible living donors.
There are proven benefits for a child having a kidney trans-
plant rather than staying on dialysis, especially during puberty
and adolescence [1–3, 13]. Both peritoneal dialysis and hemo-
dialysis are associated with a worse QoL and an unsatisfactory
growth rate [3, 14]. Allocation policies prioritizing children on
the deceased donor waiting list have contributed to lower
waiting times for a transplant. Sensitization status in children
is, however, associated with a decreased rate of
retransplantation after failure of the first graft [15].
Therefore, alternative solutions should be sought if sensitiza-
tion status hinders transplantation of a child.
Renal transplantation from the HLA-antibody-
incompatible living donors have not been undertaken so far
in pediatric recipients, perhaps due to uncertainty about long-
term outcomes and the lack of well-established desensitization
protocols in children. Long-term outcomes of living-donor
renal transplants in children are superior to transplants from
deceased donors. The failed first kidney transplant from a
deceased donor does not negatively influence the outcome
of the second transplant from the living donor [16]. The
long-term outcomes of HLA-incompatible renal transplants
in adults are superior to remaining on dialysis [8], and expan-
sion of pediatric HLA-antibody-incompatible transplantation
will allow assessment of this in children.
Experience with ABO-incompatible pediatric renal trans-
plantation provided the basis for optimizing antibody removal
procedures in pediatric transplant recipients requiring anti-
body removal in the perioperative period or for treating
antibody-mediated rejection [17–19]. There are recognized
side effects of plasma exchange, such as clotting disturbances,
hypoalbuminemia, and fluid shifts into the interstitial space,
but these usually do not extend beyond a few days after anti-
body removal session and can be appropriately managed.
Fig. 1 Posttransplant course of the first pediatric HLA-incompatible living-donor renal transplant in UK. Donor-specific antibodies and plasma
creatinine during the first month. PEX plasma exchange, TX transplant, BX biopsy, D day posttransplant
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Extracorporeal Immunoadsorbtion with columns specific for
Fc antibody fragment has several advantages over convention-
al plasma exchange: It allows processing of higher volumes of
plasma during one session and therefore efficient and specific
anti-HLA antibody removal without loosing important plasma
proteins, such as anticoagulation factors. We use
immunoadsorption columns for our adult antibody-
incompatible program but have reserved it for patients who
require multiple sessions of antibody removal. This is because
the effect on coagulation and fluid shifts are problematic in
this situation. Normally, we prefer plasma exchange or
double-filtration plasmapheresis, as this is a cheaper alterna-
tive compared with immunoadsorption. If no more than two
plasma exchange sessions are required to achieve negative
crossmatch as estimated by PEX, then benefits from
immunoadsoption are questionable.
ATG was used for the first HLA-antibody-incompatible
pediatric transplant and alemtuzumab for the second. We are
planning to continue with the latter as an induction agent of
choice. The use of ATG at induction limits options for treat-
ment of severe rejection, which is not uncommon following
HLA-antibody-incompatible transplants. We therefore advo-
cate using alemtuzumab rather than ATG. There is no evi-
dence that either of these agents is superior to another regard-
ing long-term outcomes (rejection rate; incidence of infectious
complications andmalignancy; graft and patient survival), and
therefore, the use of ATG is not arguable, especially as in
some transplant centers alemtuzumab is not available for kid-
ney transplant recipients.
There is debate about whether a more reactive immune
system in children puts them at a higher risk of acute rejection.
Acute and chronic antibody-mediated rejection leads to re-
duced renal allograft survival in HLA-antibody-incompatible
renal transplantation [11, 20]. Desensitization and aggressive
immunosuppression raises concerns about the risk of infective
complications. In our cases, antibody-mediated rejection was
absent even in the presence of DSA. We made similar obser-
vations in some of our adult patients with high levels of DSA,
where possibly a process of accommodation takes place [21,
22].
Preventing sensitization in pediatric patients requiring di-
alysis remains paramount. There has been an increase in the
percentage of sensitized patients on the waiting list due to both
their previous transplants and frequent blood transfusions [7].
Transfusion of blood products represents a potentially avoid-
able source of sensitization. In a study by Scornik et al., trans-
fusions induced sensitization in up to 35% of patients aged 5–
20 years compared with 7.5 % of patients >20 years [23, 24].
As development of anti-HLA antibodies due to blood transfu-
sion is greater in children and decreases with advancing age,
avoidance of pretransplant transfusion should be practiced.
Prior transfusion is a proven risk factor for kidney graft loss
in children [2].
The place of living-donor HLA-antibody-incompatible re-
nal transplantation in children is ill defined. In our opinion, the
kidney-sharing scheme should always be explored first be-
cause it gives the patient the chance of receiving a well-
matched living-donor kidney with an immunologically low-
risk transplant on a standard immunosuppressive regimen.
However, in the broadly sensitized child, multiple runs in
the sharing scheme are unlikely to yield results. Since the
introduction of NLDKSS in the UK in January 2012, only
one child has matched thus far, and this was with an ABO-
incompatible donor [25].
In rare circumstances, a highly sensitized child has an
HLA-compatible living donor. If this is not the case, the op-
tion of HLA-incompatible living-donor transplant should be
explored. Our practice is to perform a test plasma exchange to
assess feasibility for HLA-incompatible transplant. We mea-
sure how antibody removal can reduce the flow crossmatch
and the level of donor-specific antibodies. Presence of repeat-
ed mismatches with the previous graft puts the patient at
higher immunological risk of rejection. We offer the national
living donor sharing scheme for all our highly sensitized chil-
dren from the UK. Not all families are keen to participate, and
for many patients, it is unlikely to have a match due to the
broad sensitization, ethnicity, and type of blood group. These
issues are discussed with the family to assist them in their
decision-making process. After a few unsuccessful runs, we
consider an HLA-incompatible direct transplant. We devel-
oped an algorithm supporting the decision-making process
for sensitized children who are referred to our center
(Fig. 2). Direct HLA-incompatible renal transplantation can
be offered when an alternative HLA-compatible living donor
is not available, cRF is >85 %, and results of a test PEX
confirm its feasibility. Risk stratification is performed on an
individual basis, as high DSA without broad sensitization
Fig. 2 Algorithm supporting decision-making process as to whether to
consider HLA-incompatible renal transplantation in a child. PEX plasma
exchange, DSAs donor-specific antibodies, cRF calculated reaction
frequency
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(cRF 30–85 %), and certain donor and recipient blood group
combinations would facilitate matching in the sharing scheme
and make a direct HLA-antibody-incompatible transplant a
less attractive alternative.
Although we advocate the attempt of matching a pedi-
atric recipient with a compatible donor through paired
exchange, this option is not available for children in many
countries. In these circumstances, desensitization and
HLA-antibody-incompatible renal transplantation would
be the only chance for a highly sensitized child to receive
a kidney from a living donor. Additionally, apart from
experiencing long waiting times for deceased-donor kid-
ney due to level of sensitization, children in some coun-
tries might not have this option at all. An example would
be Japan, where deceased donation is still rare due to
cultural traditions. Again, this highlights a demand in
the transplant community for a desensitization protocol
enabling HLA-antibody-incompatible renal transplanta-
tion of highly sensitized pediatric recipients.
In summary, our work provided evidence that pediatric
HLA-antibody-incompatible renal transplantation is feasible
and should be considered in certain circumstances.
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